<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=11351&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="415199" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites.                All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml.                Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days:                1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19                2. Prime ChAdOx1 nCOV-19; Boost BNT162b2                3. Prime BNT162b2; Boost BNT162b2                4. Prime BNT162b2; Boost ChAdOx1 nCOV-19                Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms:                1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost)                2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost)                3. Prime BNT162b2; Boost BNT162b2 (28 day boost)                4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost)                5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost)                6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost)                7. Prime BNT162b2; Boost BNT162b2 (84 day boost)                8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost)                The duration of follow-up will be one y&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;immunology cohort bnt first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;immunology cohort&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;immunology cohort chadox first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;immunology cohort&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 84 day boost chadox first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 28 day boost chadox first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 84 day boost&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 28 day boost&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 84 day boost&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 28 day boost&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 84 day boost bnt first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;general cohort 28 day boost bnt first&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414250" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites. All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml.    Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2  3. Prime BNT162b2; Boost BNT162b2  4. Prime BNT162b2; Boost ChAdOx1 nCOV-19  Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost) 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost)3. Prime BNT162b2; Boost BNT162b2 (28 day boost)4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost)5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost)6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost)7. Prime BNT162b2; Boost BNT162b2 (84 day boost)8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost)The duration of follow-up will be one year from the first vaccination for each participant.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (28 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost BNT162b2 (28 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost BNT162b2 (28 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost BNT162b2 (84 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost ChAdOx1 nCOV-19 (28 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (84 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost ChAdOx1 nCOV-19 (84 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost BNT162b2 (84 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="240797" class="table-">
                
                <td>Feb. 11, 2021, 12:45 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites.                All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml.                Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days:                1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19                2. Prime ChAdOx1 nCOV-19; Boost BNT162b2                3. Prime BNT162b2; Boost BNT162b2                4. Prime BNT162b2; Boost ChAdOx1 nCOV-19                Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms:                1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost)                2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost)                3. Prime BNT162b2; Boost BNT162b2 (28 day boost)                4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost)                5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost)                6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost)                7. Prime BNT162b2; Boost BNT162b2 (84 day boost)                8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost)                The duration of follow-up will be one y&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (28 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (84 day boost)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost BNT162b2 (28 day boost)&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost ChAdOx1 nCOV-19 (28 day boost)&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime ChAdOx1 nCOV-19, Boost BNT162b2 (84 day boost)&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost ChAdOx1 nCOV-19 (84 day boost)&quot;, &quot;treatment_id&quot;: 1443, &quot;treatment_name&quot;: &quot;Bnt162b2+chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine+non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost BNT162b2 (28 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;Prime BNT162b2, Boost BNT162b2 (84 day boost)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites. All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml. Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 3. Prime BNT162b2; Boost BNT162b2 4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost) 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost) 3. Prime BNT162b2; Boost BNT162b2 (28 day boost) 4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost) 5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost) 6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost) 7. Prime BNT162b2; Boost BNT162b2 (84 day boost) 8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost) The duration of follow-up will be one y", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "immunology cohort bnt first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "immunology cohort", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "immunology cohort chadox first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "immunology cohort", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 84 day boost chadox first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 28 day boost chadox first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 84 day boost", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 28 day boost", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 84 day boost", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 28 day boost", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 84 day boost bnt first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "general cohort 28 day boost bnt first", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites. All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml. Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 3. Prime BNT162b2; Boost BNT162b2 4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost) 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost)3. Prime BNT162b2; Boost BNT162b2 (28 day boost)4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost)5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost)6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost)7. Prime BNT162b2; Boost BNT162b2 (84 day boost)8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost)The duration of follow-up will be one year from the first vaccination for each participant.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (28 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost BNT162b2 (28 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost BNT162b2 (28 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost BNT162b2 (84 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost ChAdOx1 nCOV-19 (28 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (84 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost ChAdOx1 nCOV-19 (84 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost BNT162b2 (84 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]
Feb. 11, 2021, 12:45 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "A total of 820 participants; consisting of an immunology cohort who will receive their booster vaccine dose after 28 days (n=100) and a general cohort (n=720). Half of the general cohort participants (n=360) will receive their booster vaccine after 28 days; and half will receive their booster vaccine after 84 days. Both cohorts will be stratified by study sites. All doses are given by intramuscular injection. The dose of ChAdOx1 nCOV-19 is 0.5 ml; the dose of BNT162b2 is 0.3 ml. Within the immunology cohort (n=100) participants will be randomised using stratified block randomisation 1:1:1:1 with a block size of 4 to the following arms receiving their booster vaccine dose after 28 days: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 3. Prime BNT162b2; Boost BNT162b2 4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 Within the general cohort participants (n=720) will be randomised using stratified block randomisation 1:1:1:1:1:1:1:1 with random block sizes of 8 or 16 to the following arms: 1. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (28 day boost) 2. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (28 day boost) 3. Prime BNT162b2; Boost BNT162b2 (28 day boost) 4. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (28 day boost) 5. Prime ChAdOx1 nCOV-19; Boost ChAdOx1 nCOV-19 (84 day boost) 6. Prime ChAdOx1 nCOV-19; Boost BNT162b2 (84 day boost) 7. Prime BNT162b2; Boost BNT162b2 (84 day boost) 8. Prime BNT162b2; Boost ChAdOx1 nCOV-19 (84 day boost) The duration of follow-up will be one y", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (28 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost ChAdOx1 nCOV-19 (84 day boost)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost BNT162b2 (28 day boost)", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost ChAdOx1 nCOV-19 (28 day boost)", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime ChAdOx1 nCOV-19, Boost BNT162b2 (84 day boost)", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost ChAdOx1 nCOV-19 (84 day boost)", "treatment_id": 1443, "treatment_name": "Bnt162b2+chadox1 ncov-19", "treatment_type": "Rna based vaccine+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost BNT162b2 (28 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Prime BNT162b2, Boost BNT162b2 (84 day boost)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]